Significant discounts to broader pharmaceutical industry valuations on projected 2031 earnings make some high-quality mid-cap biotech stocks attractive. Many have cleared Phase 3 trials or reached more advanced stages, and some may reach profitability without more capital, an advantage if financing tightens. Selling these stocks to chase speculative biotech or large pharma at historically elevated multiples makes little sense. x.com 

Hims & Hers, Nautilus Biotechnology, Viking Therapeutics, Protagonist Therapeutics and Eli Lilly have 10x potential as peptide-related stocks; peptides will create generational wealth this year. Nautilus has a $230 million market cap, Viking $3.5 billion, Protagonist $9.1 billion and Lilly $1.1 trillion. x.com  x.com  x.com  x.com  x.com 

Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.com 

Biotech stocks are breaking out of a five-year range because the threat from oil and interest rates was priced in years ago. Many of the most undervalued growth stocks are now in biotech, and research discovery is getting a boost from AI, making it perhaps the sector with most to gain from AI productivity. Charts support it: daily volume spikes have tended to mark major bottoms, the weekly held its quarterly averages to form a base, and the monthly shows a healthy pullback to the one-year EMA. … Show more

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Money keeps rotating into healthcare, which is where market strength is. The rotation into biotech continues, with leveraged biotech exposure offering the fireworks. Pharma offers steadier, broad exposure with no dominant holding and a chart that is fine enough. x.com  x.com 

Alexandria Real Estate Equities is priced for permanent impairment of irreplaceable life science infrastructure. Its labs in Boston, San Diego and the Bay Area serve biotech and pharma demand that pauses and then snaps back. Biotech venture funding is stabilizing, IPO windows are reopening and Big Pharma has billions for M&A, which flows to Alexandria. New lab construction has slowed sharply, tightening supply into 2026-2027, and the stock trades at a steep discount to replacement cost. x.com 

PTC Therapeutics is a favored biotech pick as Citi sees higher revenue from its Sephience drug than management does, with a $108 price target. The broader biotech sector is also breaking out. x.com  x.com